Clinical Trial Update: Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the effect of the A1 adenosine receptor agonist capadenoson on ventricular heart rate in patients with persistent or permanent atrial f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Capadenoson (Capadenoson)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED